Back to Journals » Psoriasis: Targets and Therapy » Volume 14

Do NSAIDs Trigger or Exacerbate Psoriasis? [Response to Letter]

Authors Balak DMW, Hajdarbegovic E

Received 13 September 2024

Accepted for publication 2 October 2024

Published 5 October 2024 Volume 2024:14 Pages 121—122

DOI https://doi.org/10.2147/PTT.S496118



Deepak MW Balak,1 Enes Hajdarbegovic2

1Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Dermatology, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands

Correspondence: Deepak MW Balak, Email [email protected]


xView the original paper by Dr Balak and colleagues

This is in response to the Letter to the Editor


Dear editor

We appreciate Dr. Shaikh’s insightful comments on our narrative review on drug-induced psoriasis.1,2 While we acknowledge that previous studies have suggested a link between non-steroidal anti-inflammatory drugs (NSAIDs) and the onset or exacerbation of psoriasis, the evidence supporting a causal role of NSAIDs in drug-induced and drug-aggravated psoriasis remains limited.3

The review of Fry et al, referenced by Dr. Shaikh, highlights studies dating from the 1980s that report anecdotal associations between psoriasis exacerbations and the use of topical and oral indomethacin.4 However, these studies lack robust data to confirm causality. The case-control and case-crossover study by Cohen et al reported an association between NSAID use and psoriasis in patients hospitalized with severe disease.5 However, important confounders, such as NSAID use for psoriatic arthritis, were not taken into consideration, leaving room for potential bias. Similarly, the cited reference of Grau et al, available only as a conference abstract, was based on an uncontrolled telephone questionnaire, making it highly susceptible for recall and prescription biases.6

Of note, a large cohort study from the Nurses’ Health Study (NHS) found no significant association between regular NSAID use and an increased risk of developing psoriasis.7

Taken together, we believe that the current body of evidence does not warrant advising against the use of NSAIDs in psoriasis patients.3 In line with this, current clinical guidelines continue to recommend NSAIDs as a first-line treatment option for managing psoriatic arthritis.8

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Shaikh S. NSAIDs: unveiling their role in drug-induced psoriasis [Letter]. Psoriasis. 2024;14:101–102. doi:10.2147/PTT.S492761

2. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis. 2017;7:87–94. doi:10.2147/PTT.S126727

3. Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs. J Rheumatol Suppl. 2009;83:59–61. doi:10.3899/jrheum.090227

4. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606–615. doi:10.1016/j.clindermatol.2007.08.015

5. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299–303. doi:10.1080/00015550510032823

6. Grau R, Weidner K. Drug-induced psoriasis—A retrospective chart review performed at the University of Oklahoma Department of Dermatology. J Am Acad Dermatol. 2008;59:P2647.

7. Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and Acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta Derm Venereol. 2015;95(2):217–223. doi:10.2340/00015555-1855

8. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706–719. doi:10.1136/ard-2024-225531

Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.